|本期目录/Table of Contents|

[1]孟芸畅,许 可,宋 勇.新辅助免疫治疗在可切除非小细胞肺癌中的研究进展[J].中华肺部疾病杂志,2023,(05):734-738.[doi:10.3877/cma.j.issn.1674-6902.2023.05.037]
点击复制

新辅助免疫治疗在可切除非小细胞肺癌中的研究进展(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年05期
页码:
734-738
栏目:
综述
出版日期:
2023-10-20

文章信息/Info

Title:
-
作者:
孟芸畅1; 许 可2; 宋 勇1; 2
210002 南京,南京医科大学金陵医院呼吸与危重症医学科1
210002 南京,南京大学医学院附属金陵医院呼吸与危重症医学科2
Author(s):
-
关键词:
非小细胞肺癌;  免疫治疗;  新辅助
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2023.05.037
摘要:
-
Abstract:
-

参考文献/References:

1 吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
2 王洪武, 金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
3 Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CACancer J Clin, 2021, 71(3): 209-249.
4 NSCLC Meta-Analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data[J]. Lancet(London, England), 2014, 383(9928): 1561-1571.
5 Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J]. JClin Oncol, 2008, 26(21): 3552-3559.
6 Wakelee HA, Dahlberg SE, Keller SM, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer(E1505): an open-label, multicentre, randomised, phase 3 trial[J]. LancetOncol, 2017, 18(12): 1610-1623.
7 Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. New England J Med, 2018, 378(21): 1976-1986.
8 Hui R, Özgüroglu M, Villegas A, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage Ⅲ, unresectable non-small-cell lung cancer(PACIFIC): a randomised, controlled, phase 3 study[J]. Lancet Oncol, 2019, 20(12): 1670-1680.
9 Cascone T. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial[J]. Nature Med, 2021, 27: 30.
10 Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J]. Immunity, 2007, 27(1): 111-122.
11 LiB, Chan HL, Chen P. Immune checkpoint inhibitors: Basics and challenges[J]. Curr Med Chem, 2019, 26(17): 3009-3025.
12 Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease[J]. Cancer Discov, 2016, 6(12): 1382-1399.
13 Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer | Cancer Research | American Association for Cancer Research[EB/OL].[2022-04-24]. https://aacrjournals.org/cancerres/article/78/13_Supplement/1719/625995/Abstract-1719-Superior-efficacy-of-neoadjuvant.
14 Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2019, 158(1): 269-276.
15 Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 inhibitor(Sintilimab)in NSCLC[J]. J Thorac Oncol, 2020, 15(5): 816-826.
16 Gao S, Li N, Gao S, et al. Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.[J]. J Clin Oncol, 2021, 39(15_suppl): 8522.
17 Lee J, Chaft J, Nicholas A, et al. PS01.05 surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage ⅠB-ⅢB NSCLC: LCMC3 trial primary analysis[J]. JThorac Oncol, 2021, 16(3): S59-S61.
18 Carbone D, Lee J, Kris M, et al. OA06.06 Clinical/biomarker data for neoadjuvant atezolizumab in resectable stage ⅠB-ⅢB NSCLC: Primary analysis in the LCMC3 Study[J]. JThorac Oncol, 2021, 16(3): S115-S116.
19 Eichhorn F, Klotz LV, Kriegsmann M, et al. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience[J]. Lung Cancer, 2021, 153: 150-157.
20 Tong BC, Gu L, Wang X, et al. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2022, 163(2): 427-436.
21 Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J]. New England JMed, 2022: NEJMoa2202170.
22 Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer(NADIM): an open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(11): 1413-1422.
23 Provencio M, Nadal E, Insa A, et al. OA20.01 long term survival in operable stage iiia NSCLCpatients treated with neoadjuvant nivolumab plus chemotherapy-nadim study[J]. J Thorac Oncol, 2021, 16(10): S883.
24 Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stage ⅢA(N2)non-small-cell lung cancer-A multicenter single-arm phase Ⅱ trial[J]. JClin Oncol, 2021, 39(26): 2872-2880.
25 Pless M, Stupp R, Ris HB, et al. Induction chemoradiation in stage ⅢA/N2 non-small-cell lung cancer: a phase 3 randomised trial[J]. Lancet(London, England), 2015, 386(9998): 1049-1056.
26 Zhao ZR, Yang CP, Chen S, et al. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage Ⅲ non-small-cell lung cancer[J]. Oncoimmunology, 2021, 10(1): 1996000.
27 Hellmann MD, Chaft JE, William WN, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint[J]. Lancet Oncol, 2014, 15(1): e42-50.
28 Huynh C, Sorin M, Rayes R, et al. Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer[J]. LancetOncol, 2021, 22(8): 1056-1058.
29 Pataer A, Kalhor N, Correa AM, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy[J]. JThorac Oncol, 2012, 7(5): 825-832.
30 Betticher DC, Hsu Schmitz SF, Tötsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage ⅢA pN2 non-small-cell lung cancer: 5-year follow-up of a phase Ⅱ study[J]. British JCancer, 2006, 94(8): 1099-1106.
31 Liang H, Yang C, Gonzalez-rivas D, et al. Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer[J]. Transl Lung Cancer Res, 2021, 10(1): 143-155.
32 Cascone T, Weissferdt A, Godoy MCB, et al. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer[J]. Nat Commun, 2021, 12(1): 5045.
33 Kebir S, Rauschenbach L, Galldiks N, et al. Dynamic O-(2-[18F] fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases[J]. Neuro-Oncology, 2016, 18(10): 1462-1464.
34 Billan S, Kaidar-Person O, Gil Z. Treatment after progression in the era of immunotherapy[J]. Lancet Oncology, 2020, 21(10): e463-e476.
35 Chaft JE, Rimner A, Weder W, et al. Evolution of systemic therapy for stages Ⅰ-Ⅲ non-metastatic non-small-cell lung cancer[J]. Nat RevClin Oncol, 2021, 18(9): 547-557.
36 Denis M, Duruisseaux M, Brevet M, et al. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?[J]. Front Immunol, 2020, 11: 492.
37 Kaira K, Mouri A, Kato S, et al. A phase Ⅱ study of daily carboplatin plus irradiation followed by durvalumab for stage Ⅲ non-small cell lung cancer patients with PS 2 up to 74�?偆f years old and patients with PS 0 or 1 from 75 years: NEJ039A(trial in progress)[J]. BMC Cancer, 2020, 20(1): 961.
38 Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage ⅢA(N2)Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase Ⅱ Trial[J]. J Clin Oncol, 2021, 39(26): 2872-2880.

备注/Memo

备注/Memo:
通信作者: 宋 勇, Email: yong.song@nju.edu.cn
更新日期/Last Update: 2023-10-20